Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO.

Trial Profile

Evaluating primary chemotherapy with temozolomide continuative low dose in patients with low grade gliomas grade II WHO.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Acronyms TCLGG
  • Most Recent Events

    • 22 Sep 2016 Primary endpoint (Progression free survival at 12 and 24 months) has not been met,according to the results published in the Tumori.
    • 22 Sep 2016 Results published in the Tumori
    • 07 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top